[Different proliferative capacity of human fibroblasts after 17 beta-estradiol administration].
In this study the authors examined the influence of 71, beta-estradiol on cutaneous fibroblasts taken off either from healthy patients with no family history for cancer, or from patients with breast cancer. Fibroblasts were taken from the subcutaneous tissue of the mammary gland by a biopsy carried out in each patients on the same quadrant of the granular surface. Soon after biopsy, the tissue fragments have been washed, dished ed incubated in RPMI at 37 degrees C in a humidified atmosphere of 5% CO2 and 95% air. The action of the hormone was evaluated by the means of cells count for field, in 20 fields in each dish with an inverted microscope (20 x magnification). The results demonstrated that cutaneous fibroblasts from patients with breast cancer show higher values of cell density than those from healthy one. This phenomenon is present both in basal conditions and after hormonal treatment. Two different dosages were used, but only the highest (100 microliters/ml of 17, beta-estradiol) was responsible for an increase of the cell density in all of the treated patients as compared the control groups. These data suggests the presence of a threshold dosage for the estrogens. Below such a dosage there are no effects on cellular growth.